Courier Health Raises $50 Million Series B to Revolutionize the Biopharma Patient Experience

Courier Health, a technology company focused on enhancing patient experiences in the biopharma sector, has successfully raised $50 million in a Series B funding round. The round was led by Oak HC/FT, with participation from existing investors Norwest and Work-Bench. The funding announcement was made on April 22, 2026, and is expected to significantly bolster Courier Health's product innovation efforts and solidify its market position.

Founded in New York City, Courier Health aims to streamline and personalize the patient journey within the life sciences industry. The company addresses critical challenges faced by biopharma companies, including fragmented data and poor coordination in patient engagement. According to the 2026 State of Patient-Centricity report, nearly 60% of biopharma companies struggle with inactionable data, and less than 10% have the necessary data maturity to effectively utilize artificial intelligence. Courier Health's platform integrates data and systems related to patient experiences, applying AI to identify at-risk patients and facilitate seamless interactions throughout the patient journey.

The recent funding will enable Courier Health to enhance its technology, which includes intelligent workflows, user-friendly interfaces, and AI-driven automation. These features are designed to support biopharma teams in managing the end-to-end patient experience, from education and enrollment to therapy initiation and adherence. The company has experienced rapid growth, with a reported 400% increase in customers and therapies supported in 2025, as well as a doubling of its workforce to meet rising demand.

The strategic partnership with Oak HC/FT is expected to provide Courier Health with not only capital but also valuable industry insights and support. Billy Deitch, a partner at Oak HC/FT, emphasized the importance of a dedicated platform for managing patient experiences in healthcare, noting that Courier Health is well-positioned to redefine patient-centricity in the biopharma space. The investment will allow Courier Health to continue its mission of improving health outcomes for patients reliant on innovative therapies.

Looking ahead, the successful fundraising round underscores the growing recognition of the need for improved patient experience solutions within the healthcare sector. As biopharma companies increasingly seek to enhance patient engagement and streamline processes, Courier Health's innovative approach and robust technology platform may play a pivotal role in shaping the future of patient care. The funding will likely accelerate the adoption of such technologies across the industry, potentially leading to better health outcomes and increased efficiency in the delivery of biopharmaceuticals.